Table 1.

FDA approved PD-1/PD-L1 inhibitors

Drug Name	Type	Indication
Imfinzi (durvalumab)	Anti-PD-L1 checkpoint inhibitor	Locally advanced/metastatic bladder cancer progressing during/after platinum-based chemotherapy or within 12 months of chemotherapy
Tecentriq (atezolizumab)	Anti-PD-L1 checkpoint inhibitor	Locally advanced/metastatic bladder cancer progressing during/after platinum-based chemotherapy or within 12 months of chemotherapy For metastatic NSCLC that progressed during/after platinum-based chemotherapy; patients with EGFR or ALK mutation whose cancer is progressing while using approved therapy for the mutation Initial treatment of locally advanced/metastatic bladder cancer in patients ineligible for cisplatin chemotherapy, or within 12 months of chemotherapy
Bavencio (avelumab)	Anti-PD-L1 checkpoint inhibitor	1st line or 2nd line therapy for metastatic Merkel-cell carcinoma Locally advanced or metastatic bladder cancer that progressed during/after platinum-based chemotherapy or within 12 months of neoadjuvant/adjuvant treatment
Keytruda (pembrolizumab)	Anti-PD-1 checkpoint inhibitor	Metastatic NSCLC expressing PD-L1 and progressing during/after platinum-based chemotherapy; for patients with EGFR or ALK mutations whose cancer is progressing while receiving therapy for the mutation Initial treatment of unresectable/metastatic melanoma Recurrent/metastatic head and neck squamous-cell carcinoma progressing during/after platinum-based chemotherapy Initial treatment of metastatic NSCLC with PD-L1 expression and no EGFR/ALK mutation Classical Hodgkin lymphoma not responding to therapy or relapsed after ≥3 therapies Initial treatment of metastatic nonsquamous NSCLC, in combination with pemetrexed and carboplatin, with/without PD-L1 expression Initial treatment of locally advanced/metastatic bladder cancer in patients ineligible for cisplatin-based chemotherapy Locally advanced/metastatic bladder cancer progressing during/after platinum-based chemotherapy, or within 12 months of chemotherapy Any unresectable/metastatic solid tumor with a certain genetic marker and disease progression after previous treatment, and for colorectal cancer progressing after fluoropyrimidine, Eloxatin (oxaliplatin), + irinotecan regimen
Opdivo (nivolumab)	Anti-PD-1 checkpoint inhibitor	Metastatic squamous NSCLC progressing during/after platinum-based chemotherapy Unresectable/metastatic melanoma without BRAFV600 mutation, in combination with Yervoy (ipilimumab) Metastatic nonsquamous NSCLC progressing during/after platinum-based chemotherapy; patients with EGFR or ALK mutations whose cancer progresses while using approved therapy for the mutation Advanced renal-cell carcinoma after anti-angiogenic therapy Unresectable/metastatic melanoma, in combination with Yervoy, with/without BRAF mutation Metastatic melanoma with a BRAFV600 mutation or melanoma that cannot be removed surgically Relapsed/progressing classical Hodgkin lymphoma after autologous HSCT + Adcetris (brentuximab vedotin), or after 3 systemic therapies Recurrent/metastatic squamous-cell head and neck cancer progressing during/after platinum-based therapy Locally advanced/metastatic bladder cancer progressing during/after platinum-based chemotherapy, or within 12 months of chemotherapy

Column 3 indications information obtained from Clinicaltrials.gov